Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26041729 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Valentina D'Aiuto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Asthma, Eosinophils. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Severe asthma (SA) is a chronic inflammatory condition affecting approximately 10% of asthmatic patients, and eosinophils are considered key pathogenetic actors in a significant number of patients. Biological therapies have been demonstrated to improve asthma control by decreasing exacerbation rates and reducing the use of oral corticosteroids. In this context, phenotyping and endotyping patients with SA is essential for selecting the most effective therapeutic approach. For this purpose, biomarkers such as IgE, absolute blood eosinophil count, and fractional exhaled nitric oxide (FeNO) are crucial in defining a patient’s inflammatory profile. Their integration provides a framework for classifying asthma into T2-high, T2-mild, or T2-low categories, guiding personalized treatment strategies. By incorporating multiple biomarkers into a unified model, it is possible to better stratify patients and optimize biologic therapy selection, paving the way for improved outcomes in SA management. This review aims to evaluate the role of phenotyping and endotyping SA patients, with particular attention to the impact of eosinophilic inflammation and combinatory biomarkers on decision-making processes for the selection of biological therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy.
- Head and Neck Section, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, 80131 Naples, Italy.
- Post-Graduate Program in Clinical Immunology and Allergy, University of Naples Federico II, 80131 Naples, Italy.
- Center for Basic and Clinical Immunology Research (CISI) University of Naples Federico II, 80131 Naples, Italy.
- World Allergy Organization (WAO) Center of Excellence, 80131 Naples, Italy.
ORCID-Profile: Ilaria Mormile, Francescopaolo Granata, Antonio Romano, Francesca Della Casa, Amato de Paulis
Zitieren
APA
D'Aiuto, V., Mormile, I., Granata, F., Romano, A., Della Casa, F., Mignogna, G., de Paulis, A., & Rossi, F. W. (2025). Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041729
Vancouver
D'Aiuto V, Mormile I, Granata F, Romano A, Della Casa F, Mignogna G, et al. Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041729
BibTeX
@article{DAiuto2025,
author = {D'Aiuto, Valentina and Mormile, Ilaria and Granata, Francescopaolo and Romano, Antonio and Della Casa, Francesca and Mignogna, Gabriele and de Paulis, Amato and Rossi, Francesca Wanda},
title = {Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26041729}
}
EUVIMED